Cancer Aware · Patient & Family Guide

How Doctors Choose Treatment

A treatment plan combines the cancer's features with your health, priorities and practical circumstances. The aim is to offer useful benefit while avoiding unnecessary harm.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 12 of 25

Treatment planning
  1. Confirm pathology, extent and prior treatment
  2. Integrate molecular group and recurrence risk
  3. Discuss intent, benefits, harms and patient priorities
  4. Agree a multidisciplinary plan and reassessment

What you will learn

  • Understand stage, recurrence risk and treatment intent.
  • Prepare for a multidisciplinary discussion.
  • Ask about benefits, alternatives and uncertainty.

The information that matters

The team considers histological type, grade, myometrial invasion, LVSI, cervical involvement, nodes and any disease elsewhere. Molecular classification adds information about prognosis and treatment sensitivity. ER can refine NSMP risk and support hormonal-treatment decisions; HER2 may matter in selected advanced cancers. A plan made before all results return may appropriately change afterwards.

Stage and risk group are not synonyms. Two stage I cancers may have different recommendations because of histology, molecular group or LVSI. Conversely, a patient with a favourable molecular profile may avoid treatment that would previously have been considered solely from grade. The complete context is essential.

Treatment intent and options

PurposeWhat it means
Definitive treatmentMain treatment intended to eradicate known disease
Adjuvant treatmentAdditional treatment after surgery to reduce recurrence risk
Salvage treatmentTreatment for recurrence, sometimes still with curative intent
Disease controlSlow or shrink cancer and preserve quality of life when cure is unlikely
Supportive and palliative careRelieve symptoms and support wellbeing at any stage

Observation after appropriate surgery is an active, evidence-based choice for many low-risk patients. It includes follow-up and a symptom plan. It does not mean the cancer was ignored. Palliative care can be provided alongside curative or life-prolonging treatment and does not mean that all anticancer treatment has stopped.

The multidisciplinary team

A gynaecological oncologist, pathologist, radiologist, radiation oncologist and medical oncologist may review the case together. Nurses, genetic counsellors, fertility specialists, physiotherapists, dietitians and psychological or palliative-care professionals contribute according to need. Ask who is responsible for communicating the shared recommendation and arranging the next step.

When results are unusual or options differ, expert pathology or imaging review can prevent treatment based on a mistaken assumption. A second opinion can be useful before irreversible fertility loss or complex recurrence surgery. It should be organized without unnecessary delay.

Your health and priorities

Fitness is more than age. Kidney function, neuropathy, heart or lung disease, autoimmune conditions, mobility and support at home may change treatment safety. A geriatric or frailty assessment can identify needs that are not obvious from a brief clinic visit. Adjusted treatment is not automatically inferior care; it may better match the likely benefit and burden.

Discuss fertility wishes before treatment. Also raise sexual health, caregiving duties, travel, costs, work and cultural or religious concerns. These are legitimate parts of treatment planning. If language is a barrier, a professional interpreter can help preserve privacy and accuracy.

Making an informed choice

Ask what benefit is expected in people with similar features, what uncertainty remains and which side effects may be lasting. Absolute benefits are often easier to understand than relative risk reductions. Ask what would happen with observation or an alternative, and whether a clinical trial is relevant. Trial participation should be voluntary and based on a clear explanation of known and unknown risks.

Questions and take-home messages

Before leaving, confirm the intent, proposed sequence, pending tests, start date and urgent-contact route. A written treatment summary can reduce confusion when several teams are involved. Shared decision-making does not require you to become an oncologist; it means your priorities and informed preferences are part of the decision.

Related chapters

References and review status

Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy